Abstract

Sustained activation of NF-κB is one of the causative factors for various liver diseases, including liver inflammation and hepatocellular carcinoma (HCC). It has been known that activating the NF-κB signal by hepatitis B virus X protein (HBx) is implicated in the development of HCC. However, despite numerous studies on HBx-induced NF-κB activation, the detailed mechanisms still remain unsolved. Recently, p22-FLIP, a cleavage product of c-FLIPL, has been reported to induce NF-κB activation through interaction with the IκB kinase (IKK) complex in primary immune cells. Since our previous report on the interaction of HBx with c-FLIPL, we explored whether p22-FLIP is involved in the modulation of HBx function. First, we identified the expression of endogenous p22-FLIP in liver cells. NF-κB reporter assay and electrophoretic mobility shift assay (EMSA) revealed that the expression of p22-FLIP synergistically enhances HBx-induced NF-κB activation. Moreover, we found that HBx physically interacts with p22-FLIP and NEMO and potentially forms a ternary complex. Knock-down of c-FLIP leading to the downregulation of p22-FLIP showed that endogenous p22-FLIP is involved in HBx-induced NF-κB activation, and the formation of a ternary complex is necessary to activate NF-κB signaling. In conclusion, we showed a novel mechanism of HBx-induced NF-κB activation in which ternary complex formation is involved among HBx, p22-FLIP and NEMO. Our findings will extend the understanding of HBx-induced NF-κB activation and provide a new target for intervention in HBV-associated liver diseases and in the development of HCC.

Highlights

  • The cellular anti-apoptotic protein c-FLIP is an inhibitor of apoptosis triggered by a death receptor-mediated signal [1]

  • We previously showed that c-FLIPL and c-FLIPS are expressed in liver cells [33], until now, the existence of p22-FLIP has not yet been identified in liver cells

  • As NF-kB activation is demonstrated to be closely related with liver diseases and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) [17], we first investigated whether the p22-FLIP protein is present in Huh7 human hepatoma cells

Read more

Summary

Introduction

The cellular anti-apoptotic protein c-FLIP is an inhibitor of apoptosis triggered by a death receptor-mediated signal [1]. A number of studies have shown that c-FLIPL blocks procaspase 8 activation through recruitment of the death-inducing signaling complex (DISC) by interaction with its death effecter domain (DED). All c-FLIP isoforms and p22-FLIP have two DED domains, which are essential for the inhibition of death receptor-induced apoptosis [1,2,3,4,5,6]. P22-FLIP is generated by cellular cleavage from c-FLIPL or c-FLIPS and has been shown to induce NF-kB activation through interaction with the IkB kinase (IKK) complex in immune cells [6]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call